Real-life experience in switching to new extended half-life products at European haemophilia centres

Flora Peyvandi, Isabella Garagiola, Marco Boscarino, Aislin Ryan, Cedric Hermans, Michael Makris

Research output: Contribution to journalArticle

Abstract

The concept of replacement therapy in haemophilia is changing significantly thanks to the switch from standard products to extended half-life products. These novel drugs are showing beneficial effects overcoming current prophylaxis limitations by reducing the infusion frequency, maintaining a higher trough level to ensure a lower risk of bleeding, and making treatment significantly less distressing to patients by improving the quality of life. Real-life data on the efficacy of novel drugs and their impact on routine management of haemophilia A and B patients are still limited. This manuscript reports the results of a European survey conducted by the European Association for Haemophilia and Allied Disorders (EAHAD) at the beginning of 2018 on the clinical management of patients using extended half-life recombinant FVIII and FIX fusion products, since at the time of the survey none of the PEGylated products were available yet. We report data on the efficacy of these novel drugs by 33 European haemophilia centres that have already switched to extended half-life fusion products, showing a significant reduction in the number of infusions and a satisfactory trough levels in the clinical care of haemophilia patients, with a greater impact for haemophilia B.

Original languageEnglish
Pages (from-to)946-952
JournalHaemophilia
Volume25
Issue number6
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Hemophilia A
Half-Life
Hemophilia B
Pharmaceutical Preparations
Patient Care
Quality of Life
Hemorrhage
Therapeutics
Surveys and Questionnaires

Keywords

  • extended half-life products
  • hemophilia
  • infusion
  • treatment
  • trough level

ASJC Scopus subject areas

  • Hematology
  • Genetics(clinical)

Cite this

Real-life experience in switching to new extended half-life products at European haemophilia centres. / Peyvandi, Flora; Garagiola, Isabella; Boscarino, Marco; Ryan, Aislin; Hermans, Cedric; Makris, Michael.

In: Haemophilia, Vol. 25, No. 6, 01.01.2019, p. 946-952.

Research output: Contribution to journalArticle

@article{0542307ed20f4dabbe151a4c4ff18714,
title = "Real-life experience in switching to new extended half-life products at European haemophilia centres",
abstract = "The concept of replacement therapy in haemophilia is changing significantly thanks to the switch from standard products to extended half-life products. These novel drugs are showing beneficial effects overcoming current prophylaxis limitations by reducing the infusion frequency, maintaining a higher trough level to ensure a lower risk of bleeding, and making treatment significantly less distressing to patients by improving the quality of life. Real-life data on the efficacy of novel drugs and their impact on routine management of haemophilia A and B patients are still limited. This manuscript reports the results of a European survey conducted by the European Association for Haemophilia and Allied Disorders (EAHAD) at the beginning of 2018 on the clinical management of patients using extended half-life recombinant FVIII and FIX fusion products, since at the time of the survey none of the PEGylated products were available yet. We report data on the efficacy of these novel drugs by 33 European haemophilia centres that have already switched to extended half-life fusion products, showing a significant reduction in the number of infusions and a satisfactory trough levels in the clinical care of haemophilia patients, with a greater impact for haemophilia B.",
keywords = "extended half-life products, hemophilia, infusion, treatment, trough level",
author = "Flora Peyvandi and Isabella Garagiola and Marco Boscarino and Aislin Ryan and Cedric Hermans and Michael Makris",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/hae.13834",
language = "English",
volume = "25",
pages = "946--952",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "6",

}

TY - JOUR

T1 - Real-life experience in switching to new extended half-life products at European haemophilia centres

AU - Peyvandi, Flora

AU - Garagiola, Isabella

AU - Boscarino, Marco

AU - Ryan, Aislin

AU - Hermans, Cedric

AU - Makris, Michael

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The concept of replacement therapy in haemophilia is changing significantly thanks to the switch from standard products to extended half-life products. These novel drugs are showing beneficial effects overcoming current prophylaxis limitations by reducing the infusion frequency, maintaining a higher trough level to ensure a lower risk of bleeding, and making treatment significantly less distressing to patients by improving the quality of life. Real-life data on the efficacy of novel drugs and their impact on routine management of haemophilia A and B patients are still limited. This manuscript reports the results of a European survey conducted by the European Association for Haemophilia and Allied Disorders (EAHAD) at the beginning of 2018 on the clinical management of patients using extended half-life recombinant FVIII and FIX fusion products, since at the time of the survey none of the PEGylated products were available yet. We report data on the efficacy of these novel drugs by 33 European haemophilia centres that have already switched to extended half-life fusion products, showing a significant reduction in the number of infusions and a satisfactory trough levels in the clinical care of haemophilia patients, with a greater impact for haemophilia B.

AB - The concept of replacement therapy in haemophilia is changing significantly thanks to the switch from standard products to extended half-life products. These novel drugs are showing beneficial effects overcoming current prophylaxis limitations by reducing the infusion frequency, maintaining a higher trough level to ensure a lower risk of bleeding, and making treatment significantly less distressing to patients by improving the quality of life. Real-life data on the efficacy of novel drugs and their impact on routine management of haemophilia A and B patients are still limited. This manuscript reports the results of a European survey conducted by the European Association for Haemophilia and Allied Disorders (EAHAD) at the beginning of 2018 on the clinical management of patients using extended half-life recombinant FVIII and FIX fusion products, since at the time of the survey none of the PEGylated products were available yet. We report data on the efficacy of these novel drugs by 33 European haemophilia centres that have already switched to extended half-life fusion products, showing a significant reduction in the number of infusions and a satisfactory trough levels in the clinical care of haemophilia patients, with a greater impact for haemophilia B.

KW - extended half-life products

KW - hemophilia

KW - infusion

KW - treatment

KW - trough level

UR - http://www.scopus.com/inward/record.url?scp=85070776148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070776148&partnerID=8YFLogxK

U2 - 10.1111/hae.13834

DO - 10.1111/hae.13834

M3 - Article

AN - SCOPUS:85070776148

VL - 25

SP - 946

EP - 952

JO - Haemophilia

JF - Haemophilia

SN - 1351-8216

IS - 6

ER -